Accepted Manuscript

Limiting the protein corona: A successful strategy for *in vivo* active targeting of anti-HER2 nanobody-functionalized nanostars

Antoine D'Hollander, Hilde Jans, Greetje Vande Velde, Charlotte Verstraete, Sam Massa, Nick Devoogdt, Tim Stakenborg, Serge Muyldermans, Liesbet Lagae, Uwe Himmelreich

PII: S0142-9612(17)30015-7

DOI: 10.1016/j.biomaterials.2017.01.007

Reference: JBMT 17890

To appear in: *Biomaterials*

Received Date: 28 May 2016

Revised Date: 5 January 2017

Accepted Date: 6 January 2017

Please cite this article as: D'Hollander A, Jans H, Velde GV, Verstraete C, Massa S, Devoogdt N, Stakenborg T, Muyldermans S, Lagae L, Himmelreich U, Limiting the protein corona: A successful strategy for *in vivo* active targeting of anti-HER2 nanobody-functionalized nanostars, *Biomaterials* (2017), doi: 10.1016/j.biomaterials.2017.01.007.

Limiting the protein corona: A successful strategy for *in vivo* active targeting of anti-HER2 nanobody-functionalized nanostars.

Antoine D'Hollander[1,2,3], Hilde Jans[1], Greetje Vande Velde[2,3], Charlotte Verstraete[1], Sam Massa[4,5], Nick Devoogdt[4,5], Tim Stakenborg[1], Serge Muyldermans[5], Liesbet Lagae[1**], Uwe Himmelreich[2,3**]

1. Department of Life Science Technology, Imec, Kapeldreef 75, 3001 Leuven, Belgium
2. Faculty of Medicine, Department of Imaging and Pathology, Biomedical MRI unit, KU Leuven, O&N 1, Herestraat 49, 3000 Leuven, Belgium
3. Faculty of Medicine, Molecular Small Animal Imaging Center (MoSAIC), KU Leuven O&N 1 Herestraat 49, 3000 Leuven, Belgium
4. In Vivo Cellular and Molecular Imaging Laboratory, Vrije Universiteit Brussel (VUB), Laarbeeklaan 103 Building K, 1090 Brussels, Belgium
5. Laboratory of Cellular and Molecular Immunology, Vrije Universiteit Brussel (VUB), Pleinlaan 2 Building E, 1050 Brussels, Belgium

** Both authors have contributed equally.